Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer

Pembrolizumab, either as a type of monotherapy or in combination with cytotoxic anticancer agents, is effective in the treatment of advanced non-small cell lung cancer (NSCLC). However, the development of cancer cachexia may adversely affect anticancer drug therapy. The present study investigated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Hironori, Araki, Ayumu, Iihara, Hirotoshi, Kaito, Daizo, Hirose, Chiemi, Kinomura, Motohiko, Yamazaki, Mizuki, Endo, Junki, Inui, Toshiya, Yanase, Komei, Sasaki, Yuka, Gomyo, Takenobu, Sakai, Chizuru, Kawae, Daisuke, Kitamura, Yu, Fukui, Masachika, Kobayashi, Ryo, Ohno, Yasushi, Suzuki, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892465/
https://www.ncbi.nlm.nih.gov/pubmed/35251642
http://dx.doi.org/10.3892/mco.2022.2524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892465/
https://www.ncbi.nlm.nih.gov/pubmed/35251642
http://dx.doi.org/10.3892/mco.2022.2524

Ejemplares similares